PMID- 35583251
OWN - NLM
STAT- MEDLINE
DCOM- 20221024
LR  - 20221116
IS  - 1460-2385 (Electronic)
IS  - 0931-0509 (Linking)
VI  - 37
IP  - 11
DP  - 2022 Oct 19
TI  - Usefulness of urinary biomarkers to estimate the interstitial fibrosis surface in 
      diabetic nephropathy with normal kidney function.
PG  - 2102-2110
LID - 10.1093/ndt/gfac185 [doi]
AB  - BACKGROUND: Kidney biopsies of patients with diabetic nephropathy (DN) and normal 
      kidney function may exhibit interstitial fibrosis (IF) without reduction of 
      glomerular filtration rate (GFR) because of hyperfiltration. The aim of our study 
      was to analyse the performance of a set of biomarkers of tubular injury to 
      estimate the extent of IF in patients with DN and normal kidney function. 
      METHODS: This cross-sectional study included 118 adults with DN diagnosed by 
      kidney biopsy and GFR >/=90 mL/min/1.73 m2 and a control group of healthy subjects. 
      We measured the urinary excretion of monocyte chemoattractant protein-1 (MCP-1) 
      neutrophil gelatinase-associated lipocalin (NGAL), kidney injury molecule-1 
      (KIM-1), liver-type fatty acid-binding protein (L-FABP), beta2-microglobulin and 
      dickkopf-3 protein (DKK-3) at the time of kidney biopsy. GFR was measured by 
      chromium-51 labeled ethylenediamine tetraacetic acid (Cr-EDTA) (measured GFR). IF 
      was quantified using a quantitative morphometric procedure. Predictive 
      multivariate models were developed to estimate the IF surface. RESULTS: Patients 
      with DN showed significantly higher levels of DKK-3, MCP-1 and L-FABP and 
      significantly lower levels of epidermal growth factor (EGF) than healthy 
      controls. There were no significant between-group differences in the levels of 
      beta2-microglobulin, KIM-1 or NGAL. IF was negatively associated with EGF and 
      positively with age, proteinuria, MCP-1, DKK-3 and L-FABP, but not with 
      beta2-microglobulin, KIM-1, NGAL or GFR. The best model to predict IF surface 
      accounted for 59% of its variability and included age, proteinuria, EGF, DKK-3 
      and MCP-1. CONCLUSIONS: Our study provides a model to estimate the IF in DN that 
      can be useful to assess the progression of IF in patients with normal kidney 
      function.
CI  - (c) The Author(s) 2022. Published by Oxford University Press on behalf of the ERA.
FAU - Gonzalez, Jorge
AU  - Gonzalez J
AD  - Servicio de Nefrologia Hospital Arnau de Vilanova, Lleida, Spain.
FAU - Jatem, Elias
AU  - Jatem E
AD  - Servicio de Nefrologia Hospital Arnau de Vilanova, Lleida, Spain.
FAU - Roig, Jordi
AU  - Roig J
AD  - Servicio de Nefrologia Hospital Arnau de Vilanova, Lleida, Spain.
FAU - Valtierra, Naiara
AU  - Valtierra N
AD  - Nephrology Department, Vall d'Hebron Institut de Recerca, Barcelona, Spain.
FAU - Ostos, Elena
AU  - Ostos E
AD  - Nephrology Department, Vall d'Hebron Institut de Recerca, Barcelona, Spain.
FAU - Abo, Anabel
AU  - Abo A
AD  - Servicio de Anatomia Patologica, Hospital Arnau de Vilanova, Lleida, Spain.
FAU - Santacana, Maria
AU  - Santacana M
AD  - Servicio de Anatomia Patologica, Hospital Arnau de Vilanova, Lleida, Spain.
AD  - Nephrology Department, Institut de Recerca Biomedica August Pi I Sunyer, Lleida, 
      Spain.
FAU - Garcia, Alicia
AU  - Garcia A
AD  - Nephrology Department, Institut de Recerca Biomedica August Pi I Sunyer, Lleida, 
      Spain.
FAU - Segarra, Alfons
AU  - Segarra A
AD  - Servicio de Nefrologia Hospital Arnau de Vilanova, Lleida, Spain.
AD  - Nephrology Department, Vall d'Hebron Institut de Recerca, Barcelona, Spain.
AD  - Nephrology Department, Institut de Recerca Biomedica August Pi I Sunyer, Lleida, 
      Spain.
AD  - Servicio de Nefrologia Hospital Vall d'Hebron, Barcelona, Spain.
LA  - eng
PT  - Journal Article
PL  - England
TA  - Nephrol Dial Transplant
JT  - Nephrology, dialysis, transplantation : official publication of the European 
      Dialysis and Transplant Association - European Renal Association
JID - 8706402
RN  - 0 (Lipocalin-2)
RN  - 0 (Chemokine CCL2)
RN  - 62229-50-9 (Epidermal Growth Factor)
RN  - 9G34HU7RV0 (Edetic Acid)
RN  - 0 (Biomarkers)
RN  - 0 (Fatty Acid-Binding Proteins)
SB  - IM
MH  - Humans
MH  - Adult
MH  - *Diabetic Nephropathies/diagnosis/etiology/metabolism
MH  - Lipocalin-2
MH  - Chemokine CCL2/urine
MH  - Epidermal Growth Factor
MH  - Cross-Sectional Studies
MH  - Edetic Acid
MH  - Glomerular Filtration Rate
MH  - Biomarkers/urine
MH  - Fatty Acid-Binding Proteins/urine
MH  - Proteinuria/pathology
MH  - Kidney
MH  - Fibrosis
MH  - *Diabetes Mellitus
OTO - NOTNLM
OT  - biomarkers
OT  - chronic renal failure
OT  - diabetic nephropathy
OT  - fibrosis
OT  - interstitial fibrosis
EDAT- 2022/05/19 06:00
MHDA- 2022/10/25 06:00
CRDT- 2022/05/18 08:23
PHST- 2022/01/19 00:00 [received]
PHST- 2022/05/19 06:00 [pubmed]
PHST- 2022/10/25 06:00 [medline]
PHST- 2022/05/18 08:23 [entrez]
AID - 6588052 [pii]
AID - 10.1093/ndt/gfac185 [doi]
PST - ppublish
SO  - Nephrol Dial Transplant. 2022 Oct 19;37(11):2102-2110. doi: 10.1093/ndt/gfac185.